Browsing: HCP Access Only

Explore the latest breakthroughs in HIV treatment, including advancements in antiretroviral therapy (ART), stem cell therapy, and gene editing, offering new hope for patients.

Recent studies have found that not all forms of exercise yield equal benefits. Specifically, recent studies suggest that occupational PA might have unexpected consequences for cognitive function. In this article, we delve into the research, exploring why occupational PA could potentially impact our brains differently.

A recent publication in JAMA Ophthalmology has brought to light potential risks associated with the use of semaglutide, a medication often prescribed for managing type 2 diabetes (T2D) and obesity.

Recent advances reveal that an epilepsy drug may reverse Alzheimer’s symptoms, paving the way for innovative dementia treatments.

Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

How does artemisinin, a compound from Traditional Chinese Medicine (TCM) plant Artemisia get involved with PCOS management? It has been shown to be able to modulate testosterone and insulin.

As gout prevalence climbs, new research backs Treat-to-Target strategies for effective management to reduce uric acid levels and mean gout flare rate.

Eczema, or atopic dermatitis, is a chronic, relapsing, inflammatory skin condition characterised by the development of intense eczematous lesions and severe itching. This condition results in significant discomfort and distress to sufferers. Typically, eczema develops in childhood and in approximately 80% of children with eczema, the disease persists into adulthood. In higher-income countries, rapid urbanisation has led to the disease affecting around 20% of children and up to 10% of adults. Globally, eczema impacts around 194.4 million people. Alarmingly, the prevalence of eczema is increasing worldwide, including in large parts of Asia. In Southeast Asia alone, between 3.7- 13.5% of children aged 6-7 years old suffer from eczema. It becomes crucial to understand the factors contributing to eczema and how to manage it effectively.